Detail akcie Adamis Pharma Rg online

Business Summary: DMK Pharmaceuticals Corporation is a commercial stage neuro-biotech company. The Company is focused on developing and commercializing products for the treatment of opioid overdose and substance-use disorders. Its ZIMHI (naloxone) is FDA approved for the treatment of opioid overdose. It is focused on developing novel therapies for opioid use disorder (OUD) and other important neuro-based conditions where patients are currently underserved. Its technologies are at the forefront of endorphin-inspired drug design with its mono, bi-, and tri-functional small molecules that simultaneously modulate critical networks in the nervous system. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. Its other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
Financial Summary: BRIEF: For the nine months ended 30 September 2023, DMK Pharmaceuticals Corp revenues decreased 44% to $1.5M. Net loss before extraordinary items decreased 22% to $17.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and development decrease of 82% to $1.7M (expense), PPP2 Loan Contingent Loss decrease from $1.8M (expense) to $0K.